Related Experiment Videos
MLL: a histone methyltransferase disrupted in leukemia
1Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 413b Stellar Chance Laboratories, Philadelphia, PA 19104, USA. jhess@mail.med.upenn.edu
Trends in Molecular Medicine
|October 7, 2004
Summary
Rearrangements of the Mixed Lineage Leukemia (MLL) gene are linked to aggressive leukemias. These genetic changes disrupt normal blood cell development by altering Hox gene expression, suggesting new therapeutic targets.
Area of Science:
- Genetics
- Hematology
- Oncology
Background:
- The Mixed Lineage Leukemia (MLL) gene at chromosome 11q23 is crucial for regulating Hox gene expression.
- Aberrant MLL gene rearrangements, including fusions, duplications, and amplifications, are implicated in aggressive acute leukemias in pediatric and adult patients.
Purpose of the Study:
- To elucidate the role of MLL gene rearrangements in the pathogenesis of acute leukemia.
- To explore the mechanism by which MLL alterations lead to dysregulated Hox gene expression and blocked hematopoietic differentiation.
- To identify potential therapeutic strategies targeting MLL-associated leukemia.
Main Methods:
- Analysis of MLL gene rearrangements in leukemia patient samples.
- Investigation of MLL's role in regulating Hox gene expression via promoter binding and histone modification.
- Assessment of the impact of MLL alterations on hematopoietic differentiation.
Main Results:
- MLL rearrangements, such as MLL fusions and amplifications, were found to upregulate Hox gene expression.
- This upregulation of Hox genes appears to cause a critical block in hematopoietic differentiation, contributing to leukemia development.
Conclusions:
- MLL gene rearrangements are key drivers of aggressive acute leukemias by disrupting normal hematopoietic differentiation through Hox gene dysregulation.
- Targeting Hox gene upregulation or the activity of Hox proteins presents a promising avenue for future MLL-leukemia therapies.